| # | Title | Journal | Year | Citations |
|---|
| 1 | Hematological findings and complications of COVID‐19 | American Journal of Hematology | 2020 | 1,354 |
| 2 | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis | American Journal of Hematology | 2005 | 1,179 |
| 3 | Autoimmune hemolytic anemia | American Journal of Hematology | 2002 | 564 |
| 4 | Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management | American Journal of Hematology | 2020 | 507 |
| 5 | Hematologic parameters in patients with COVID‐19 infection | American Journal of Hematology | 2020 | 496 |
| 6 | TEG and ROTEM: Technology and clinical applications | American Journal of Hematology | 2014 | 488 |
| 7 | Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations | American Journal of Hematology | 1990 | 428 |
| 8 | Treatment of sinus histiocytosis with massive lymphadenopathy (rosai-dorfman disease): Report of a case and literature review | American Journal of Hematology | 2002 | 394 |
| 9 | Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute-sponsored working group | American Journal of Hematology | 1988 | 389 |
| 10 | The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up | American Journal of Hematology | 2010 | 385 |
| 11 | The cost of health care for children and adults with sickle cell disease | American Journal of Hematology | 2009 | 368 |
| 12 | Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management | American Journal of Hematology | 2016 | 366 |
| 13 | FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease | American Journal of Hematology | 2010 | 353 |
| 14 | Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment | American Journal of Hematology | 2019 | 352 |
| 15 | An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer | American Journal of Hematology | 2019 | 340 |
| 16 | Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies | American Journal of Hematology | 2018 | 336 |
| 17 | Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry | American Journal of Hematology | 2003 | 331 |
| 18 | Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination | American Journal of Hematology | 2021 | 331 |
| 19 | Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature | American Journal of Hematology | 2008 | 327 |
| 20 | Methemoglobin—It's not just blue: A concise review | American Journal of Hematology | 2007 | 321 |
| 21 | Diagnosis of cobalamin deficiency I: Usefulness of serum methylmalonic acid and total homocysteine concentrations | American Journal of Hematology | 1990 | 320 |
| 22 | Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors | American Journal of Hematology | 2012 | 320 |
| 23 | Pericytes and vessel maturation during tumor angiogenesis and metastasis | American Journal of Hematology | 2010 | 318 |
| 24 | The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports | American Journal of Hematology | 2010 | 308 |
| 25 | Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment | American Journal of Hematology | 2019 | 307 |
| 26 | Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma | American Journal of Hematology | 2019 | 305 |
| 27 | VAD-based regimens as primary treatment for multiple myeloma | American Journal of Hematology | 1990 | 291 |
| 28 | Definitions of the phenotypic manifestations of sickle cell disease | American Journal of Hematology | 2010 | 291 |
| 29 | Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring | American Journal of Hematology | 2018 | 291 |
| 30 | Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management | American Journal of Hematology | 2017 | 290 |
| 31 | Polymerase chain reaction amplification applied to the determination of β-like globin gene cluster haplotypes | American Journal of Hematology | 1989 | 289 |
| 32 | Methemoglobinemia | American Journal of Hematology | 1993 | 285 |
| 33 | Acute myeloid leukemia: 2019 update on risk‐stratification and management | American Journal of Hematology | 2018 | 283 |
| 34 | The number of people with sickle‐cell disease in the United States: national and state estimates | American Journal of Hematology | 2010 | 280 |
| 35 | Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases | American Journal of Hematology | 1985 | 274 |
| 36 | Acquired hemophilia A: Updated review of evidence and treatment guidance | American Journal of Hematology | 2017 | 267 |
| 37 | HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases | American Journal of Hematology | 2008 | 266 |
| 38 | Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major | American Journal of Hematology | 1993 | 263 |
| 39 | Fucoidan induces apoptosis of human HS-Sultan cells accompanied by activation of caspase-3 and down-regulation of ERK Pathways | American Journal of Hematology | 2005 | 260 |
| 40 | Estimated annual numbers of US acute‐care hospital patients at risk for venous thromboembolism | American Journal of Hematology | 2007 | 257 |
| 41 | Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML | American Journal of Hematology | 2011 | 254 |
| 42 | Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis | American Journal of Hematology | 2015 | 247 |
| 43 | Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection | American Journal of Hematology | 2005 | 246 |
| 44 | Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes | American Journal of Hematology | 2008 | 244 |
| 45 | Constitutive neutrophil apoptosis: Mechanisms and regulation | American Journal of Hematology | 2008 | 244 |
| 46 | Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML | American Journal of Hematology | 2015 | 242 |
| 47 | Acquired hemophilia A: A concise review | American Journal of Hematology | 2005 | 238 |
| 48 | Factors associated with survival in a contemporary adult sickle cell disease cohort | American Journal of Hematology | 2014 | 235 |
| 49 | Thrombosis in COVID‐19 | American Journal of Hematology | 2020 | 235 |
| 50 | Acute myeloid leukemia: 2013 update on risk‐stratification and management | American Journal of Hematology | 2013 | 234 |
